|
|
|
| Investigation and rationality evaluation of Butyphthalide use in 78 hospitals of 7 cities |
| WANG Huiyuan ZHAO Zhigang▲ |
| Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China |
|
|
|
Abstract Objective To investigate the current situation and trend of Butyphthalide use in 7 cities of China (Beijing, Hangzhou, Guangzhou, Shanghai, Tianjin, Chengdu and Zhengzhou) and preliminarily evaluate the rationality of its use. Methods Statistical analysis was carried out on the sales amount, defined daily doses and Defined daily dose consumption of Butyphthalide in 78 hospitals of 7 cities from 2013 to 2017. Results In the 5 years, the proportion of male and female patients using Butyphthalide was about 2∶1 in the 7 cities, and their age was mainly between 71-90 years old (41%). The top three primary diagnoses were cerebral infarction (15.5%), cerebrovascular disease (2.4%) and cerebral infarction (1.7%). Drug utilization index (DUI): Beijing > Tianjin > Chengdu > Hangzhou > Shanghai > Guangzhou > Zhengzhou. Defined daily doses (DDDs): Beijing > Hangzhou > Guangzhou > Shanghai > Chengdu > Zhengzhou. Defined daily dose consumption (DDDc): Zhengzhou > Shanghai > Guangzhou > Beijing > Tianjin > Hangzhou. Conclusion Beijing, Hangzhou, Guangzhou and Shanghai are the biggest cities in consuming Butyphthalide. In Zhengzhou, Shanghai and Guangzhou, the price level is the highest and the economic burden is the heaviest. The doctors in Zhengzhou area were too cautious, or the dose was too small, and did not reach the therapeutic effect. The drugs are in accordance with the recommended Chinese guidelines and the most reasonable prescriptions of dosage are in order: Beijing > Tianjin > Chengdu > Hangzhou, and these 4 cities are in good condition.
|
|
|
|
|
|
[1] Chen XL，Wang KW. The fate of medications evaluated for ischemic strokepharmacotherapy over the period 1995-2015 [J]. Acta Pharm，2016，6（6）：522-530.
[2] Wang YL，Zhao XQ，Jiang Y，et al. Prevalence，knowledge，and treatment of transient ischemic attacks in China [J]. Neurology，2015，84（1）：2354-2361.
[3] Mozaffarian D，Benjamin EJ，Go AS，et al. Heart disease and stroke statistics——2016 update：a report from the American heart association [J]. Circulation，2016，133（1）：38-60.
[4] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志，2010，43（2）：146-153.
[5] 国家药典委员会.中华人民共和国药典临床用药须知[M].北京：人民卫生出版社，2010：256-284.
[6] 陈新谦，金有豫.新编药物学[M].17版.北京：人民卫生出版社，2011：459-478.
[7] 吴娟，陈永.丁苯酞对急性脑梗死患者临床疗效及血液流变学的影响[J].重庆医学，2012，41（33）：3488-3489.
[8] Xiong Z，Lu W，Zhu L，et al. Dl-3-n-butylphthalide treatment enhances hemodynamics and ameliorates memory deficits in rats with chronic cerebral hypoperfusion [J]. Front Aging Neurosci，2017，26（6）：1-13.
[9] 李玉文.急性缺血性脑卒中患者血清IL-6的表达及与TOAST分型和OCSP分型的关系[J].中国老年学杂志，2015，35（17）：4862—4863.
[10] Bucaretchi F，De Capitani EM，Fernandes CB，et al. Fatal ischemic stroke following Tityusserrulatus scorpion sting in apatient with essential thrombocythemia [J]. Clin Toxicol（Phila），2016，54（9）：867-870.
[11] Lei H，Zhao CY，Liu DM，et al. l-3-N- Butylphthalideattenuates β- amyloid-induced toxicity in neuroblastoma SH -SY5Y cells through regulating mitochondrion-mediated apoptosis and MAPK signaling [J]. J Asian Nat Prod Res，2014，16（8）：854-864.
[12] Wang X，Wang L，Sheng X，et al. Design，synthesis andbiological evaluation of hydrogen sulfide releasing derivatives of 3-N-butylphthalide as potential antiplatelet and antithrombotic agents [J]. Org Biomol Chem，2014，12（31）：5995 -6004.
[13] 施晓耕，黄如训，刘春岭，等.丁苯酞对高血压性脑卒中预防作用的实验研究[J].中国神经精神疾病杂志，2007， 33（1）：486-489.
[14] Zhang T，Jia W，Sun X. 3-N-Butylphthalide NBP reduces apoptosis and enhances vascular endothelial growth factor VEGF up-regulation in diabetic rats [J]. Neurol Res，2010，32（2）：390-396.
[15] Liao SJ，Lin JW，Pei Z，et al. Enhance dangiogenesis with dl-3n-bu-tylphthalide treatment after focal cerebral ischemiain [J]. Brain Res，2009，1289（2）：69-78.
[16] Troy M，Sepideh AH. Neuroprotectant drug shows promise in human ischemic stroke [J]. World Neurosurgery，2013， 79（3）：408-411.
[17] Antonino T，Rosaria P，Valentina A，et al. Developing drug strategies for the neuroprotective treatment of acute ischemic stroke [J]. Expert Review of Neurotherapeutics，2015，15（11）：1271-1284.
[18] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[19] 张素娥，王月花.丁苯酞对急性脑梗死的疗效研究[J].北方药学，2017，14（12）：87-88.
[20] 王德任，刘鸣，吴波等，丁苯酞治疗急性缺血性卒中随机对照试验的系统评价[J].中国循证医学杂志，2010， 10（2）：189-195.
[21] 刘培尧，袁浩字.丁苯酞注射液治疗急性脑梗死疗效及安全性Meta分析[J].中国药业，2015，24（24）：88-90. |
|
|
|
